Liu, Xiaomei I.
Momper, Jeremiah D.
Rakhmanina, Natella Y.
Green, Dionna J.
Burckart, Gilbert J.
Cressey, Tim R.
Mirochnick, Mark
Best, Brookie M.
van den Anker, John N.
Dallmann, André
Funding for this research was provided by:
Foundation for the National Institutes of Health (UM1AI068632, UM1AI068616, UM1AI106716, HHSN275201800001I)
Article History
First Online: 25 May 2020
Compliance with Ethical Standards
:
: Xiaomei I. Liu, Jeremiah D. Momper, Natella Y. Rakhmanina, Dionna J. Green, Gilbert J. Burckart, Tim R. Cressey, Mark Mirochnick, Brookie M. Best, John N. van den Anker, and André Dallmann have no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. André Dallmann is an employee of Bayer AG and involved in OSP software development. The results from this study were presented in part at the American College of Clinical Pharmacology Annual Meeting, Washington, DC, September 2018.
: Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health, all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT LC), and by NICHD contract number HHSN275201800001I. The NIH awards numbers 5T32HD087969-03 and 5T32HD087969-02 also support this project.